MYOKARDIA
MyoKardia is a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing targeted therapies for the treatment of rare cardiovascular diseases. The company's focus is on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It utilizes its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy-hypertrophic cardiomyopathy and dilated cardiomyopathy. The company was founded in 2012 and is headquartered in Brisbane, California.
MYOKARDIA
Industry:
Biopharma Biotechnology Health Care Medical Therapeutics
Founded:
2012-09-01
Address:
Brisbane, California, United States
Country:
United States
Website Url:
http://www.myokardia.com
Total Employee:
251+
Status:
Closed
Contact:
650 741 0900
Email Addresses:
[email protected]
Total Funding:
98 M USD
Technology used in webpage:
SPF Amazon IPv6 Google Apps For Business Microsoft Azure DNS YouTube Google Amazon Virginia Region Pound Sterling Japanese Yen
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
BridgeBio Pharma
BridgeBio Pharma investment in Series B - MyoKardia
Cowen Group
Cowen Group investment in Series B - MyoKardia
Casdin Capital
Casdin Capital investment in Series B - MyoKardia
Cormorant Asset Management
Cormorant Asset Management investment in Series B - MyoKardia
Perceptive Life Sciences
Perceptive Life Sciences investment in Series B - MyoKardia
Cormorant Asset Management
Cormorant Asset Management investment in Venture Round - MyoKardia
Cowen Group
Cowen Group investment in Venture Round - MyoKardia
Sanofi
Sanofi investment in Venture Round - MyoKardia
Casdin Capital
Casdin Capital investment in Venture Round - MyoKardia
BridgeBio Pharma
BridgeBio Pharma investment in Venture Round - MyoKardia
Official Site Inspections
http://www.myokardia.com
- Host name: 165.89.235.72
- IP address: 165.89.235.72
- Location: Trenton United States
- Latitude: 40.2187
- Longitude: -74.7404
- Metro Code: 504
- Timezone: America/New_York
- Postal: 08629
More informations about "MyoKardia"
MyoKardia - Crunchbase Company Profile & Funding
MyoKardia is a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing targeted therapies for the …See details»
MyoKardia - LinkedIn
MyoKardia | 15,053 followers on LinkedIn. Driven by the heart | We officially combined with Bristol Myers Squibb to further strengthen our scientific capabilities and treatments for cardiovascular ...See details»
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
Oct 5, 2020 MyoKardia’s Board of Directors unanimously recommends that MyoKardia shareholders tender their shares in the tender offer. The transaction is subject to customary …See details»
Myokardia Inc - AnnualReports.com
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare …See details»
MyoKardia - Contacts, Employees, Board Members, Advisors
MyoKardia is a clinical-stage biopharmaceutical company that develops targeted therapies for the treatment of rare cardiovascular diseases. ... Experience the new Crunchbase, powered by AI …See details»
MyoKardia Company Profile - Office Locations, Competitors ... - Craft
MyoKardia Summary. Company Summary. Overview. MyoKardia is a company that discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected …See details»
MyoKardia Inc Company Profile - MyoKardia Inc Overview
Up-to-date MyoKardia Inc company overview including funding information, company profile, key statistics, peer comparison and more.See details»
Bristol Myers Squibb acquires MyoKardia, expanding its …
Mar 1, 2021 Introduction: On October 5th, Bristol Myers Squibb announced a definitive agreement to acquire MyoKardia for $225 per share, totaling the deal value to approximately …See details»
MyoKardia (USA) Funding: $98M - medicalstartups.org
Apr 2, 2025 MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare …See details»
MyoKardia 2025 Company Profile: Valuation, Investors ... - PitchBook
MyoKardia Inc is a US-based clinical-stage biopharmaceutical company which is engaged in discovering, developing and commercializing targeted therapies for the treatment of serious …See details»
MyoKardia CEO and Key Executive Team | Craft.co
MyoKardia's Chief Executive Officer, Director is Tassos Gianakakos. Other executives include William Fairey, Executive Vice President, Chief Commercial Officer; Bob McDowell, Chief …See details»
Bristol Myers Squibb acquires MyoKardia Inc., a biomedical …
Nov 17, 2020 MyoKardia Inc., a biomedical company founded in 2013, develops small molecule therapeutics that address key clinical needs for patients with genetic heart disease. The …See details»
Bristol Myers Squibb Completes Acquisition of MyoKardia, …
Nov 17, 2020 Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of MyoKardia, Inc. in an all cash transaction for approximately $13.1 …See details»
Bristol Myers Squibb to Acquire MyoKardia
This report contains “forward-looking statements” relating to the acquisition of MyoKardia by Bristol Myers Squibb and the development and commercialization of certain biological …See details»
MyoKardia - Funding, Financials, Valuation & Investors - Crunchbase
MyoKardia is registered under the ticker NASDAQ:MYOK . Their stock opened with $10.00 in its Oct 29, 2015 IPO. Stock Symbol NASDAQ:MYOK ; Money Raised at IPO $54M; IPO Share …See details»
MyoKardia: The Precision Cardiac Medicine Company with
Jul 7, 2020 At least that’s the mantra at the heart of MyoKardia, a California-based biotech company that is developing precision medicine for cardiovascular diseases (CVDs). “We want …See details»
Kardigan, founded by veterans of MyoKardia, raise $300M for new …
Jan 10, 2025 When Bristol Myers Squibb bought the heart disease-focused biotech MyoKardia for $13 billion in cash in the fall of 2020, it was seen as an endorsement of advances being …See details»
Bristol Myers expands heart drug business with $13 billion deal for ...
Oct 5, 2020 Bristol Myers Squibb Co said on Monday it would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments, ahead of the potential loss of sales …See details»
AHA Scientific Sessions 2020 | MyoKardia Congresses
MyoKardia is a pioneering biopharmaceutical company discovering and developing targeted treatments for patients diagnosed with serious and underserved cardiovascular diseases. Our …See details»
Why Give | American Heart Association
Yes, the American Heart Association is a 501(c)(3) nonprofit organization, and your donation is tax-deductible as allowed by law. Our Tax ID is 13-5613797. Can I make a donation in honor …See details»